Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios

Oncology Research

Volumn 16, Issue 8, 2007, Pages 361-374

  Harasym, Troy O ^a   Tardi, Paul G ^a   Harasym, Natashia L ^a   Harvie, Pierrot ^a   Johnstone, Sharon A ^a   Mayer, Lawrence D ^a,b,c  

^a Celator Pharmaceuticals Corp   (Canada)

^b Celator Pharmaceuticals Inc   (United States)

^c Celator Pharmaceuticals   (Canada)

Author keywords

Colorectal cancer; Combination chemotherapy; Floxuridine; Irinotecan; Liposome delivery; Synergy

Indexed keywords

FLOXURIDINE; IRINOTECAN; LIPOSOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL;

EID: 34548685592     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783980937     Document Type: Article

References (25)

1. Khayat, D.; Gil-Delgado, M.; Antoine, E. C.; Coeffic, D.; Benhammouda, A.; Grapin, J. P.; Bastian, G. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology 12:64-67; 1998.
2. Cornella, P.; Casaretti, R.; De Vita, F.; Avallone, A.; Orditura, M.; Petrillo, A.; Gravina, A.; Faranda, A.; Comis, S.; Cornelia, G.; Catalano, G. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A phase I study of the Southern Italy Cooperative Oncology Group. Ann. Oncol. 10:915-921; 1999.
3. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343:905-914; 2000.
4. Douillard, J. Y.; Cunningham, D.; Roth, A. D.; Navarro, M.; James, R. D.; Karasek, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355(9209):1041-1047; 2000.
5. Frei, III, E. Clinical studies of combination chemotherapy for cancer. In: Chou, T. C.; Rideout, D. C., eds. Synergism and antagonism in chemotherapy. San Diego, CA: Academic Press; 1991:103-108.
6. DeVita, Jr., V. T. Principles of cancer management: Chemotherapy. In: DeVita, Jr., V. T.; Hellman, S.; Rosenberg, S. A., ed. CANCER: Principles & practice of oncology, vol. 1. Philadelphia, PA: Lippincott-Raven; 1997:333-347.
7. Tannock, I. The basic science of oncology. In: Tannock, I. F.; Hill, R. P., eds. New York: McGraw-Hill; 1992: 139-196.
8. Mayer, L. D.; Harasym, T. O.; Tardi, P. G.; Harasym, N. L.; Shew, C. R.; Johnstone, S. A.; Ramsay, E. C.; Bally, M. B.; Janoff, A. S. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5:1854-1863; 2006.
9. Harasym, T. O.; Tardi, P. G.; Johnstone, S. A.; Bally, M. B.; Janoff, A. S.; Mayer, L. D. Fixed drug ratio liposome formulations of combination cancer therapeutics. In: Gregoriadis, G., ed. Liposome technology, Volume III: Interactions of liposomes with the biological milieu, 3rd ed. Boca Raton, FL: CRC Press; 2006:25-48.
10. Reitemeier, R. J.; Moertel, C. G.; Hahn, R. G. Comparison of 5-fluorouracil and 5-fluoro-2′deoxyuridine in treatment of patients with advanced adenocarcinoma of colon or rectum. Cancer Chemother. Rep. 44:39-43; 1965.
11. Ansfield, F. J.; Curreri, A. R. Further clinical comparison between 5-fluorouracil (5-FU) and 5-fluoro-2′-deoxyuridine (5-FUDR). Cancer Chemother. Rep. 32:101-105; 1963.
12. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63; 1983.
13. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55; 1984.
14. Chou, T. C.; Hayball, M. P. CalcuSyn: Windows software for dose effects analysis. Montana: Biosoft; 1996:1-56.
15. Euhus, D. M.; Hudd, C.; LaRegina, M. C.; Johnsom, F. E. Tumor measurement in the nude mouse. J. Surg. Oncol. 31:229-234; 1986.
16. Tomayka, M. M.; Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24:148-154; 1989.
17. Tardi, P. G.; Gallagher, R. C.; Johnstone, S.; Harasym, N.; Webb, M.; Bally, M. B.; Mayer, L. D. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 1768:678-687; 2007.
18. Dicko, A.; Tardi, P.; Mayer, L. D. Spectroscopic characterization of irinotecan encapsulation in copper gluconate/triethanolamine containing liposomes. Int. J. Pharmaceut. in press.
19. Pavillard, V.; Kherfellah, D.; Richard, S.; Robert, J.; Montaudon, D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br. J. Cancer 85:1077-1083; 2001.
20. Johnston, J. S.; Johnson, A.; Gan, Y.; Guillaume Wientjes, M.; Au, L. S. Synergy between 3′-Azido-3′-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharmaceut. Res. 20:957-961; 2003.
21. Zastre, J.; Anantha, M.; Ramsay, E.; Bally, M. Irinotecan-cisplatin interactions assessed in cell-based screening assays: Cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother. Pharmacol. 60:91-102; 2007.
22. Frazier, A.; Dicko, A.; Hderliter, A.; Ellena, J.; Cafiso, D.; Tardi, P.; Mayer, L. Physical state of encapsulated irinotecan is modulated by floxuridine, copper gluconate, and triethanolamine in CPX-1 liposomes. Biophys. J. 92S:3494; 2007.
23. Vaage, J.; Donovan, D.; Mayhew, E.; Uster, P.; Woodle, M. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int. J. Cancer 54:959-964; 1993.
24. Abraham, S. A.; McKenzie, C.; Masin, D.; Ng, R.; Harasym, T. O.; Mayer, L. D.; Bally, M. B. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through the use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 10:728-738; 2004.
25. Batist, G.; Chi, K.; Miller, W.; Chia, S.; Hasanbasic, F.; Fisic, A.; Mayer, L.; Swenson, C.; Janoff, A.; Gelmon, K. Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. J. Clin. Oncol. 18S:2014; 2006.